Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accessing real-time interaction between antimicrobial liposomes and live <i>Staphylococcus epidermidis</i> using surface plasmon resonance microscopy.

Biosensors & bioelectronics: X·2026
Same author

Recombinant Aspergillus fumigatus antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis.

Vaccine·2022
Same author

Barriers to concussion reporting in collegiate athletes: an analysis of a peer-led worksheet activity.

Journal of American college health : J of ACH·2022
Same author

Nano- and Macroscale Imaging of Cholesterol Linoleate and Human Beta Defensin 2-Induced Changes in <i>Pseudomonas aeruginosa</i> Biofilms.

Antibiotics (Basel, Switzerland)·2021
Same author

Cognitions That Support Concussion Reporting in Collegiate Athletes: An Analysis of a Worksheet Activity.

Health education & behavior : the official publication of the Society for Public Health Education·2021
Same author

Psychometric properties of concussion knowledge and cognitive mediators of reporting measures.

Brain injury·2021

Related Experiment Video

Updated: Jul 10, 2026

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

The VesiVax system: a method for rapid vaccine development.

Gary Fujii1, William Ernst, Jill Adler-Moore

  • 1Molecular Express, Inc., 2011 University Drive, Rancho Dominguez, CA 90220, USA. gfujii@molecularexpress.com

Frontiers in Bioscience : a Journal and Virtual Library
|November 6, 2007
PubMed
Summary

The VesiVax system engineers proteins for liposome insertion, creating potent vaccines. This platform rapidly produces effective influenza and herpes simplex virus vaccines, demonstrating protective efficacy and immune responses in animal models.

More Related Videos

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection
09:25

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Published on: May 24, 2020

Methodology for the Efficient Generation of Fluorescently Tagged Vaccinia Virus Proteins
09:27

Methodology for the Efficient Generation of Fluorescently Tagged Vaccinia Virus Proteins

Published on: January 17, 2014

Related Experiment Videos

Last Updated: Jul 10, 2026

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
09:03

Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development

Published on: June 19, 2018

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection
09:25

Rapid, Seamless Generation of Recombinant Poxviruses using Host Range and Visual Selection

Published on: May 24, 2020

Methodology for the Efficient Generation of Fluorescently Tagged Vaccinia Virus Proteins
09:27

Methodology for the Efficient Generation of Fluorescently Tagged Vaccinia Virus Proteins

Published on: January 17, 2014

Area of Science:

  • Vaccinology
  • Nanotechnology
  • Immunology

Background:

  • Conventional vaccine production can be time-consuming and may present safety concerns.
  • Developing novel vaccine platforms is crucial for rapid response to emerging infectious diseases.

Purpose of the Study:

  • To introduce the VesiVax system, a novel vaccine technology platform.
  • To demonstrate the efficacy of VesiVax-based vaccines against influenza and herpes simplex virus type 2 (HSV-2).

Main Methods:

  • Engineering proteins for stable insertion into liposomes to create nanoscale immunogens.
  • Developing VesiVax vaccines targeting influenza virus and HSV-2.
  • Testing vaccine efficacy and immunological responses in animal models.

Main Results:

  • VesiVax vaccines demonstrated significant protective efficacy against lethal doses of influenza and HSV-2 in animal studies.
  • Immunological assays indicated that VesiVax vaccines elicit both T cell and B cell responses.
  • The VesiVax platform allows for rapid engineering and production of new vaccine candidates.

Conclusions:

  • The VesiVax system offers a flexible and rapid approach to vaccine development.
  • VesiVax-based vaccines show promise for effective immunization against viral infections.
  • The platform is expected to yield vaccines with improved safety profiles compared to conventional methods.